1. Please check and comment entries here.
Table of Contents

    Topic review

    Near Infrared Photoimmunotherapy

    Subjects: Oncology
    View times: 13
    Submitted by: Hisataka Kobayashi

    Definition

    Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that uses an antibody-photoabsorber (IRDye700DX) conjugate (APC) that is activated by NIR light irradiation. A major benefit of NIR-PIT is that only APC-bound cancer cells that are exposed to NIR light are killed by NIR-PIT; thus, minimal damage occurs in adjacent normal cells. NIR-PIT has now been applied to many cancers expressing various cell-surface target proteins using monoclonal antibodies designed to bind to them. Moreover, NIR-PIT is not limited to tumor antigens but can also be used to kill specific host cells that create immune-permissive environments in which tumors grow. Moreover, multiple targets can be treated simultaneously with NIR-PIT using a cocktail of APCs. NIR-PIT has great potential to treat a wide variety of cancers by targeting appropriate tumor cells, immune cells, or both, and can be augmented by other immunotherapies. 

    1. Introduction

    Near-infrared photoimmunotherapy (NIR-PIT) (IlliminoxTM) is a newly developed cancer treatment that induces selective immunogenic cell death in targeted cells [1]. NIR-PIT utilizes an antibody–photoabsorber conjugate (APC) that is activated by NIR light, typically administered as laser light. A large body of research has developed around NIR-PIT, showing that it can kill many types of cancer cells by targeting unique transmembrane proteins overexpressed in cancer cells. Currently, a global phase III clinical trial of NIR-PIT for inoperable head and neck cancer patients is currently underway using an anti-epidermal growth factor receptor (EGFR)-antibody IRDye700DX (IR700) conjugate. In Japan, the first APC (ASP-1929, AkaluxTM, Rakuten Medical Inc., San Diego, CA, USA) targeting EGFR and utilizing a near infrared laser system (BioBladeTM, Rakten Medical Inc.) was approved for clinical use in September 2020. Although NIR-PIT has been primarily developed to use antibodies against cancer membrane antigens, it can also kill normal host cells, especially those that promote cancer cell growth, by inhibiting the immune system locally [2].
    Tumor-targeted NIR-PIT evokes a profound immune response. This can be augmented with various checkpoint inhibitors. The first such agent, ipilimumab, was a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and was approved in March 2011 to treat patients with late-stage melanoma. This class of immune checkpoint inhibitor (ICI) has continued to expand over the last decade, with many ICIs being approved. Although these agents have been highly effective in some patients, immunotherapy-related side effects, termed immune-related adverse events (irAEs), have been widely reported in various organs. irAEs occur because ICIs activate immunity throughout the body, not just in the tumor. These side effects can cause syndromes that mimic autoimmune disease in normal organs. Ideally, a comprehensive cancer therapy would selectively kill tumor cells and activate local tumor immunity. None of the existing major therapies, surgery, radiation, or chemotherapy do this. Tumor- and immune cell-targeted NIR-PIT can kill tumor cells selectively and deplete local immune suppressor cells in the tumor beds. This leads to dramatically more active immune responses against tumors without inducing irAEs in non-target tissues.

    2. NIR-PIT

    Historically, the term “photoimmunotherapy” meant targeted photodynamic therapy using antibodies conjugated with conventional photosensitizers such as hematoporphyrin based on cytotoxicity induced by reactive oxygen species (ROS) in the 1980s [3]. Various combinations of conventional photosensitizers and antibodies were tested to improve their delivery and selectivity. Due to the unfavorable chemical design that conjugated antibodies with hydrophobic chemicals, therapeutic effects were limited only on cells in vitro or tumors with intra-tumoral or intra-spatial administration in vivo. Therefore, such conjugates were not successfully applied to cancer therapy via systemic administration in vivo [4] because of insufficient delivery to the tumor due to rapid liver accumulation of conjugates promoted by the hydrophobicity of conventional photosensitizers, resulting in an insufficient accumulation of photosensitizers in the tumor [5]. Therefore, these photosensitizers have not been approved for clinical use. Furthermore, the cytotoxicity of such conjugates relied on ROS that mainly induced apoptotic cell death, yet caused non-specific damage on various parts of cells, including the cell membrane, in both targeted and adjacent non-targeted cells. In contrast, NIR-PIT (IlluminoxTM) showed selective dedicated cytotoxicity on target cells based on a photo-induced ligand release reaction rather than ROS after the systemic intravenous injection of IR700-based APCs with various antibodies. Additionally, NIR-PIT is a hybrid therapy of direct cancer cell killing induced by NIR light exposure combined with rational immune activation. Therefore, NIR-PIT is totally different from the old “photoimmunotherapy” and is now defined as IlluminoxTM.
    Nanosized particles were used as carriers of photosensitizers due to the large loading capacity [6]. Nanosized drugs have an advantage on delivery into tumor beds through permeable tumor vessels and are then retained in the tumor bed. This process is known as the enhanced permeability and retention (EPR) effect [7]. However, the EPR effect offers less than a twofold increase in nanodrug delivery compared to critical normal organs with inhomogeneous intratumor micro-distribution, resulting in failure to cure most cancers [8]. Therefore, nanosized vehicles could be a good carrier for photothermal therapy (PTT), but would not rationally be a good carrier of photosensitizers for targeted photodynamic therapy (PDT). To overcome all these problems, NIR-PIT was developed as a novel cancer treatment with high cell selectivity with minimal toxicity to adjacent cells.
    NIR-PIT utilizes an antibody conjugated with the NIR photon-absorbing silicon phthalocyanine dye IR700 [1][9][10]. When injected intravenously, APCs bind to a specific cell membrane antigen. Once bound, NIR light (approximately 690 nm) exposure kills only APC-bound target cells, sparing nearby cells which have no or minimal expression of the target antigen [1][9][11][12]. Immediately after NIR light exposure to APC, axial ligands of the IR700 molecule dissociate from the molecule, converting the APC from very hydrophilic to very hydrophobic. This change in the chemical characteristics of IR700 promotes conformational changes and aggregation of APCs that damage the cell membrane, causing weakening and eventually rupture of the cell (Figure 1). NIR-PIT can clearly be distinguished from conventional photodynamic therapy (PDT) or photothermal therapy (PTT), which rely on cytotoxic singlet oxygen and hyperthermia, respectively, and cause non-selective damage to light-exposed cells [13][14]. In addition to direct cancer-cell killing, NIR-PIT rapidly induces immunogenic cell death (ICD) [15][16], which initiates activation of the adaptive immune response, employing dead-cell-associated antigens, including calreticulin (CRT), adenosine triphosphate (ATP), high-mobility group box 1 (HMGB1), heat shock protein (Hsp) 70, and Hsp90 [17][18][19][20]. These danger signals activate local immature dendritic cells (DCs) to stimulate the presentation of tumor antigens, which are released from NIR-PIT-treated cancer cells. The DCs present these antigens to T cells, resulting in priming and educating naive T cells to become cancer-specific CD8+ T cells [15][21]. Therefore, NIR-PIT has the potential to reset anti-tumor host immunity due to ICD. These factors have contributed to the initial success of NIR-PIT.
    Figure 1. Scheme for cellular cytotoxicity induced by NIR-PIT. Antibody-photoabsorber conjugates bind to a specific cell membrane antigen. Immediately after NIR light exposure to APC, the water outside of the cells is flown into the target cell, leading to cell death. Adapted from Ref [10].

    3. NIR-PIT Targeting Cancer Cells

    Initially, NIR-PIT was developed to target cells expressing EGFR, human epidermal growth factor receptor-2 (HER2), and prostate-specific membrane antigen (PSMA) [1]. Since those early days, NIR-PIT has expanded to target a variety of transmembrane proteins using monoclonal antibodies designed to bind to these antigens. Here, we review many of the targets that have been investigated for potential use in NIR-PIT using PubMed, with “photoimmunotherapy,” “near infrared,” and “IR700” as keywords (Table 1).
    Table 1. Correspondence of molecular targets for each tumor in NIR-PIT targeting cancer cells.
    Malignant Neoplasma Target Moleclue
    EGFR HER2 CD44 CEA PDPN MSLN GPA33 TROP2 CDH-17 PD-L1 Cancer Specific Target
    Glioblastoma multiforme +       +         +  
    Head and neck Ca. ++ + ++   +         ++  
    Lung Ca. ++ ± + + + +       ++ DLL3 (SCLC)
    MPM         + +          
    Breast Ca. ++ + + +           +  
    Gastrointestinal Ca.                      
     Esophageal Ca. ++   + ± +         +  
     Gastric Ca. + + ++ +     + + + +  
     Colorectal Ca. + ± + ++     + + + +  
     Hepatic cell Ca.     +             + GPC-3
     cholangiocarcinoma     + +       +   +  
     Pancreatic Ca. + + + +   + + + + +  
    GIST                     c-KIT
    Bladder Ca. ++ + +             +  
    Prostate Ca.   ± +             + PSMA
    Cervical Ca. ++ + + ± +         +  
    Ovarian Ca. + + + + + +       +  
    Malignant melanoma                   ++ CD146
    Lymphoma                   ++ CD20, CD25, CLA

    3.1. Epidermal Growth Factor Receptor

    EGFR, belonging to the erythroblastosis oncogene B (ErbB) family, is a transmembrane tyrosine kinase receptor [22]. Physiologically, EGFR regulates epithelial tissue development and homeostasis. EGFR mutation and/or overexpression is observed in several human cancers (Figure 2A) and EGFR-targeted therapy has become a routine part of the treatment of several cancers [23]. In several tumor types (e.g., head and neck, cervical, bladder, and esophageal cancer) EGFR overexpression has been associated with poor prognosis [24]. Hence, EGFR was considered a good target for early clinical trials of NIR-PIT. Multiple studies have confirmed the therapeutic efficiency of EGFR-targeted NIR-PIT both for in vitro testing and in mouse xenograft models [1][25][26][27][28][29]. Cetuximab, which is a chimeric IgG1 monoclonal antibody and a competitive inhibitor of EGFR ligand binding, was approved for head and neck squamous cell carcinoma (HNSCC), colorectal cancer, and non-small cell lung cancer (NSCLC) patients by the FDA. EGFR overexpression is very common in HNSCC patients (up to 90%) [30]. Based on the relative ease of applying light to HNSCC tumors and the poor outcomes for patients with recurrent disease with current therapies, this setting was the logical starting point for clinical translation of NIR-PIT. The first phase 1/2 clinical trial of NIR-PIT took place in patients with recurrent HNSCC using cetuximab-IR700 conjugates and successfully concluded in late 2017 [31]. The results suggested that EGFR-targeted NIR-PIT was more effective than currently recommended second- and third-line therapies for HNSCC. Cetuximab-IR700 was conditionally approved and registered for clinical use as the first EGFR-targeted NIR-PIT drug in Japan in 2020. Investigator-initiated clinical trials against EGFR-expressing esophageal and stomach cancers using cetuximab-IR700 started in 2019 for extending applications of the drug. Theoretically, EGFR-targeted NIR-PIT could be applied to other types of cancers with EGFR overexpression [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55].
    Figure 2. The positivity proportion of (A) EGFR and (B) HER2 expressions in various cancers (ca.; carcinoma, ESCC; esophageal squamous cell carcinoma, EAC; esophageal adenocarcinoma). ((A) The numbers in the brackets show reference number. (B) Quoted from references [50][51]).

    3.2. Human Epidermal Growth Factor Receptor 2

    HER2, also known as HER2/neu, c-erbB2, or ERBB2, is a membrane tyrosine kinase and another member of the ErbB family [22]. HER2 was found to be amplified in a human breast cancer cell line 35 years ago [56]. HER2 does not bind EGF-like ligands, relying instead on heterodimerization with other ErbB family receptors for activation, which differs from other members of the ErbB family such as EGFR [57]. HER2 overexpression creates spontaneous receptor homodimers or heterodimers with other ErbB family receptors, resulting in activated oncogenic downstream signaling (e.g., PI3K/Akt/mTOR and MAPK) promoting cellular proliferation, survival, and angiogenesis [58]. In breast cancer patients, HER2 positivity rates have been reported in the range of 15% to 20% [59]. HER2 is an established therapeutic target of breast cancer and several drugs, including trastuzumab, pertuzumab, lapatinib, neratinib, and trastuzumab emtansine (T-DM1), have been approved for the treatment of HER2-positive breast cancer by the FDA. HER2 has also been detected in approximately 20% of gastric cancers [60][61]. Trastuzumab and fam-trastuzumab deruxtecan-nxki for HER2 positive gastric cancer patients have been approved by the FDA. Moreover, HER2 amplifications or mutations and HER2 overexpression have been reported in various solid tumor types (Figure 2B) [60]. For example, the overexpression rate of HER2 has been reported in 0% to 64% of esophageal cancer [62][63]. NIR-PIT utilizing trastuzumab-IR700 has been effective in xenograft models with a human breast cancer cell line, in pleural dissemination models by HER2 expressing NSCLC cells, in esophageal carcinoma cell lines in vitro, and in subcutaneous tumor models and disseminated peritoneal models with several ovarian cancer cell lines [1][64][65][66]. Combination therapy of HER2-targeted NIR-PIT and conventional chemotherapy such as 5-Fluorouracil (5-FU) rapidly induced significant tumor inhibition in a gastric cancer xenograft model [67]. Moreover, NIR-PIT with trastuzumab-IR700 and pertuzumab-IR700 conjugates showed stronger antitumor effects than with either mono conjugate in a gastric cancer xenograft model [68]. Therefore, HER2-targeted NIR-PIT is a promising therapy for various HER2 overexpressed tumors.

    3.3. Cancer Stem Cell Markers

    CD44, a non-kinase transmembrane glycoprotein, is a well-known marker of cancer stem cells (CSCs) and mediates intercellular adhesion, regulating epithelial to mesenchymal transition and cancer progression [69]. Various types of cancers, including most head and neck, gastric, lung, colorectal, and breast cancers, and hepatocellular carcinoma express CD44, making it a valuable diagnostic and prognostic marker [70]. Thus, CD44 is an important target for antibody-based therapies [71]. CD44-targeted NIR-PIT significantly suppressed tumor progression and prolonged survival in CD44-expressing syngeneic mouse models of oral squamous cell carcinoma [72]. Moreover, combined CD44-targeted NIR-PIT with programmed cell death protein 1 (PD-1) or CTLA4 checkpoint blockade was more effective in combination than as single therapies in syngeneic mouse models, including a minimally immunogenic tumor [21][73][74]. Combined CD44-targeted NIR-PIT with PD-1 blockade eradiated more than 70% of established tumors [21]. AC133, which is also a stem cell-specific glycosylation-dependent epitope of CD133, is a CSC marker found in many tumors [75]. AC133-targeted NIR-PIT suppressed tumor progression and prolonged survival for both subcutaneous and orthotopic tumor models of AC133 positive glioblastoma stem cells [76]. Thus, NIR-PIT targeting CSCs can induce significant therapeutic responses.

    3.4. Prostate-Specific Membrane Antigen

    PSMA is a well-established cell membrane marker of prostate cancer, and is expressed highest in poorly differentiated, metastatic, and hormone-refractory prostate cancer [77]. The expression level of PSMA is associated with the stage and grade of the prostate cancer, but the expression is low in normal tissues [78]. PSMA-targeted NIR-PIT significantly suppressed tumor growth and prolonged survival in mouse prostate tumor models [77]. Furthermore, PSMA-targeted small and bivalent antibody fragments, including diabodies (Db) and minibodies (Mb), were effective therapies using NIR-PIT. Localized prostate cancer would be amenable to focal therapy with a PSMA-directed NIR-PIT using light fibers inserted in the prostate. Because of its selectivity, it would be unlikely to damage nerves or sphincter muscles, yet could result in effective tumor control by direct killing and induction of anti-tumor host immunity. Therefore, NIR-PIT targeting PSMA is a reasonable approach for prostate cancer.

    3.5. Carcinoembryonic Antigen

    Carcinoembryonic antigen (CEA), a glycoprotein involved in cell adhesion, is already used as a tumor marker in various cancers, and the expression levels of CEA are related to prognosis in colorectal cancer patients [79][80][81]. More than 50 years after its initial discovery, CEA is still an excellent marker for differentiating colorectal cancer from normal tissues (98.8% of cases) and detecting positive lymph nodes [82]. Therefore, CEA is a promising target for cancer therapy. NIR-PIT targeting CEA suppressed tumor progression significantly not only in a xenograft model of gastric cancer but also in the orthotopic pancreatic tumor model without adverse effects [83][84]. For pancreatic cancer, complete tumor resection can improve overall survival. NIR-PIT could be used as an adjuvant to surgery, treating any residual pancreatic cancer. This was tested in a patient-derived orthotopic xenograft model using CEA-targeted NIR-PIT [85]. Moreover, surgery with CEA-targeted NIR-PIT reduced recurrence by targeting residual cancer cells [86]. Thus, CEA-targeted NIR-PIT could be an adjuvant to conventional cancer therapies.

    3.6. Podoplanin

    Malignant pleural mesothelioma (MPM) is a malignant tumor that originates from mesothelial cells and has an extremely poor prognosis [87][88]. Podoplanin (PDPN) is a type I transmembrane glycoprotein that is expressed in lymphatic endothelial cells, type I alveolar epithelial cells, and podocytes of the glomeruli. The antibody (D2-40) for PDPN has been used for a long time as a specific pathological diagnostic marker to distinguish lymphatic vessels from blood vessels and to verify the presence of MPM [89][90][91]. PDPN is also upregulated in various tumors, including MPM, angiosarcomas, chondrosarcomas, osteosarcomas, germ-cell tumors, gliomas, glioblastomas, dysgerminomas of the ovary, and squamous cell carcinomas of the skin, esophagus, lung, cervix, and head and neck [92][93]. For NIR-PIT, the lung and thoracic cavity can effectively transmit NIR light over long distances, because it consists mainly of air. PDPN-targeted NIR-PIT using the NZ-1 antibody demonstrated tumor suppression in both xenograft and orthotopic MPM models [87].

    3.7. Mesothelin

    Mesothelin (MSLN) is a cell-surface glycoprotein and tumor differentiation marker expressed in several tumors, including lung cancer, pancreatic cancer, ovarian cancer, and MPM [94]. MSLN can be used as a systemic diagnostic biomarker and is a target for antibody-based therapies [94][95]. MSLN-targeted NIR-PIT has been shown to be effective in mouse xenograft models [96]. NIR-PIT targeting MSLM is a promising candidate for the treatment of mesothelin-expressing tumors.

    3.8. Glycoprotein A33 Antigen

    Glycoprotein A33 antigen (GPA33) could be another target of NIR-PIT in colorectal cancer because it is highly expressed in over 95% of human colorectal cancers, more than 60% of gastric cancers, and 50% of pancreatic cancers [97]. Additionally, GPA33 exhibits limited expression in the normal intestinal epithelium [98]. GPA33-targeted NIR-PIT demonstrated tumor growth suppression in a xenograft model [99].

    3.9. Tumor-Associated Calcium Signal Transducer 2

    Tumor-associated calcium signal transducer 2 (TROP2) is a 46kD glycoprotein that plays a multifunctional cellular role, including transducing of cytoplasmic calcium. TROP2 is overexpressed in many epithelial cancers, including gastrointestinal tumors, cholangiocarcinoma, and prostate and pancreatic cancer [100]. Furthermore, it corelates with a poor prognosis in various cancers [101]. TROP2-targeted NIR-PIT inhibited tumor growth in cholangiocarcinoma and pancreatic cancer models [102]. Thus, TROP2-targeted NIR-PIT is an attractive candidate for TROP2 expressing tumors.

    3.10. Cadherin-17

    Cadherin-17 (CDH-17), a cell surface biomarker specific for gastrointestinal cancers, is a cell−cell adherent junctional molecule and plays an important role in cancer cell adhesion, progression, and metastasis [103]. Moreover, CDH-17 is highly expressed on colorectal, gastric, and pancreatic adenocarcinoma [104]. CDH17-targeted NIR-PIT inhibited tumor growth in a pancreatic and gastric xenograft model [105]. Thus, CDH-17 is another promising agent for NIR-PIT in gastrointestinal cancers.

    3.11. Delta-Like Protein 3

    Delta-like protein 3 (DLL3) is a potential therapeutic target molecule for small cell lung cancer (SCLC) and other neuroendocrine tumors that is minimally expressed in normal tissues [106]. However, rovalpituzumab tesirine, which is the first antibody targeting DLL3, was terminated on August 2019 because of the failure of the TAHOE (NCT03061812) and MERU (NCT03033511) clinical trials [107]. Notwithstanding this result, NIR-PIT targeting DLL3 in SCLC xenograft model showed marked antitumor effects [108]. NIR-PIT targeting DLL3 using rovalpituzumab could easily be translatable into the clinic since rovalpituzumab has already been used in a human clinical trial [109].

    3.12. Glypican-3

    Glypican-3 (GPC3), a 65-kDa membrane-bound heparin sulfate proteoglycan that is highly expressed in hepatic cell carcinoma (HCC) but not in normal tissue, is being evaluated as a potential therapeutic target for HCC [110][111]. GPC3-targeted NIR-PIT inhibited tumor growth compared to an untreated control in a xenograft model [112]. Moreover, the combination of GPC3-targeted NIR-PIT and the nanoparticle albumin-bound paclitaxel enhanced the therapeutic effect [113].

    3.13. c-KIT

    Gastrointestinal stromal tumors (GISTs) are the most common submucosal tumors (SMTs) of the alimentary tract [114]. SMTs are derived from mesenchymal cells and are generally covered with normal mucosa, so it is difficult to distinguish GIST from other types of SMTs by conventional endoscopy [115][116]. However, c-KIT is expressed in over 90% of GISTs on the cell membrane; therefore, it can be a molecular target for NIR-PIT [115][116]. Moreover, c-KIT-targeted NIR-PIT using anti-CD117 antibody induced acute necrotic cell death and was very effective in a GIST tumor model [115]. Thus, NIR-PIT targeting c-KIT could be a novel effective technology for GISTs.

    3.14. CD20

    Lymphoma is a diverse group of B-cell, T-cell, and natural-killer cell tumors, but the majority of lymphomas (approximately 90%) are of B-cell origin [117]. Malignant cells that originate from the B-cell lineage often express B-cell differentiation antigens such as CD19 and CD20, which can be targeted by monoclonal antibodies [118]. Utilizing anti-CD20 monoclonal antibody rituximab, CD20-targeted NIR-PIT against B-cell lymphoma significantly inhibited tumor growth [119], and the therapeutic effect of NIR-PIT was better than that of radioimmunotherapy against a xenograft model of aggressive B-cell lymphoma [120].

    3.15. Cutaneous Lymphocyte Antigen and CD25

    Mycosis fungoides is a rare cancer, however, it is the most common subtype of cutaneous T-cell lymphoma [121]. It is reported that mycosis fungoides cells express cutaneous lymphocyte antigen (CLA) [122]. CLA-targeted NIR-PIT specifically killed a mycosis fungoides cell line in vitro [123]. Thus, NIR-PIT could treat such locoregional lymphomas. Additionally, CD25, which is an α-subunit of interleukin-2 receptor and overexpressed in most cases of adult T-cell leukemia/lymphoma (ATLL), is thought to arise from the regulatory T cell (Treg) [124]. Therefore, CD25 is potentially a good target molecule for cutaneous lesions of ATLL and for Treg killing.

    3.16. CD146

    CD146 has been identified as a melanoma cell adhesion molecule. The expression of CD146 in melanoma is high and is found in 70% of primary melanomas and 90% of their lymph node metastases [125]. Wei et al. reported that CD146-targeted NIR-PIT inhibited tumor growth in a CD146-positive melanoma xenograft model [126].

    3.17. H-Type Lectin/β-D-Galactose Receptors

    Non-antibody mediated NIR-PIT has proven to be more difficult than antibody mediated NIR-PIT. However, there are some advantages of using non-antibody targeting agents such as galactosyl serum albumin (GSA), because GSA as a target is ubiquitous among ovarian cancers, whereas it is difficult to find a single antibody that will bind to all types of ovarian cancers. GSA is comprised of galactose molecules conjugated via carboxyl groups to an albumin molecule, and it binds to β-D-galactose receptors, also called H-type lectins, which are overexpressed on the surface of many ovarian tumors [127]. Although a large amount of NIR light exposure was needed for effective NIR-PIT therapy because GSA ligands were quickly internalized after binding to β-D-galactose receptors, GSA-targeted NIR-PIT specifically killed ovarian cancer cells (SHIN3) in vitro and suppressed tumor growth in a peritoneal disseminated model [128]. This may be especially useful when specific antibodies are not available for ovarian cancers. The development of similar non-antibody-based forms of NIR-PIT could therefore be an effective way of extending the utility of this novel therapy to other tumors.

    3.18. Programmed Death-Ligand 1

    PD-1 (CD279) is a T-cell immune checkpoint that suppresses autoimmunity, leading to immune tolerance of cells expressing programmed death-ligand 1 (PD-L1, CD274) [129]. Upregulated PD-L1 on these cells contributes to the development of T-cell exhaustion [130]. PD-L1 is expressed in various types of normal cells (including placenta, vascular endothelium, pancreatic islet cells, muscle, hepatocytes, epithelium, and mesenchymal stem cells, as well as on B cells, T cells, DCs, macrophages, and mast cells), but it is overexpressed in many cancer cells, including melanoma, renal cell carcinoma, NSCLC, thymoma, and ovarian and colorectal cancer [129][131]. Furthermore, PD-L1 overexpression is associated with a poor prognosis [132]. Several antibodies against PD-1/PD-L1 have recently been developed for clinical application by the FDA. PD-L1-targeted NIR-PIT using avelumab, which is a fully humanized IgG1 anti-PD-L1 monoclonal antibody (mAb), significantly inhibited tumor growth and prolonged survival in a xenograft model [133]. Thus, PD-L1-targeted NIR-PIT is another potential cancer therapy.

    This entry is adapted from 10.3390/cancers13112535

    References

    1. Mitsunaga, M.; Ogawa, M.; Kosaka, N.; Rosenblum, L.T.; Choyke, P.L.; Kobayashi, H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 2011, 17, 1685–1691.
    2. Sato, K.; Sato, N.; Xu, B.; Nakamura, Y.; Nagaya, T.; Choyke, P.L.; Hasegawa, Y.; Kobayashi, H. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci. Transl. Med. 2016, 8, 352ra110.
    3. Mew, D.; Wat, C.K.; Towers, G.H.; Levy, J.G. Photoimmunotherapy: Treatment of animal tumors with tumor-specific mono-clonal antibody-hematoporphyrin conjugates. J. Immunol. 1983, 130, 1473–1477.
    4. Lin, C.W.; Amano, T.; Rutledge, A.R.; Shulok, J.R.; Prout, G.R. Photodynamic effect in an experimental bladder tumor treated with intratumor injection of hematoporphyrin derivative. Cancer Res. 1988, 48, 6115–6120.
    5. Sobolev, A.S.; Jans, D.A.; Rosenkranz, A. Targeted intracellular delivery of photosensitizers. Prog. Biophys. Mol. Biol. 2000, 73, 51–90.
    6. Longmire, M.; Choyke, P.L.; Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine 2008, 3, 703–717.
    7. Kobayashi, H.; Turkbey, B.; Watanabe, R.; Choyke, P.L. Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates. Bioconjugate Chem. 2014, 25, 2093–2100.
    8. Nakamura, Y.; Mochida, A.; Choyke, P.L.; Kobayashi, H. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjugate Chem. 2016, 27, 2225–2238.
    9. Sato, K.; Ando, K.; Okuyama, S.; Moriguchi, S.; Ogura, T.; Totoki, S.; Hanaoka, H.; Nagaya, T.; Kokawa, R.; Takakura, H.; et al. Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Central Sci. 2018, 4, 1559–1569.
    10. Kobayashi, H.; Choyke, P.L. Near-Infrared Photoimmunotherapy of Cancer. Acc. Chem. Res. 2019, 52, 2332–2339.
    11. Mitsunaga, M.; Nakajima, T.; Sano, K.; Choyke, P.L.; Kobayashi, H. Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. Bioconjugate Chem. 2012, 23, 604–609.
    12. Nakajima, T.; Sato, K.; Hanaoka, H.; Watanabe, R.; Harada, T.; Choyke, P.L.; Kobayashi, H. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity. BMC Cancer 2014, 14, 389.
    13. Kwiatkowski, S.; Knap, B.; Przystupski, D.; Saczko, J.; Kędzierska, E.; Knap-Czop, K.; Kotlińska, J.; Michel, O.; Kotowski, K.; Kulbacka, J. Photodynamic therapy—Mechanisms, photosensitizers and combinations. Biomed. Pharmacother. 2018, 106, 1098–1107.
    14. Zhi, D.; Yang, T.; O’Hagan, J.; Zhang, S.; Donnelly, R.F. Photothermal therapy. J. Control. Release 2020, 325, 52–71.
    15. Ogawa, M.; Tomita, Y.; Nakamura, Y.; Lee, M.-J.; Lee, S.; Tomita, S.; Nagaya, T.; Sato, K.; Yamauchi, T.; Iwai, H.; et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget 2017, 8, 10425–10436.
    16. Kobayashi, H.; Furusawa, A.; Rosenberg, A.; Choyke, P.L. Near-infrared photoimmunotherapy of cancer: A new approach that kills cancer cells and enhances anti-cancer host immunity. Int. Immunol. 2021, 33, 7–15.
    17. Green, D.R.; Ferguson, T.; Zitvogel, L.; Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 2009, 9, 353–363.
    18. Kroemer, G.; Galluzzi, L.; Kepp, O.; Zitvogel, L. Immunogenic Cell Death in Cancer Therapy. Annu. Rev. Immunol. 2013, 31, 51–72.
    19. Krysko, D.; Garg, A.D.; Kaczmarek, A.; Krysko, O.; Agostinis, P.; Vandenabeele, P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12, 860–875.
    20. Galluzzi, L.; Buqué, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 2017, 17, 97–111.
    21. Nagaya, T.; Friedman, J.; Maruoka, Y.; Ogata, F.; Okuyama, S.; Clavijo, P.E.; Choyke, P.L.; Allen, C.; Kobayashi, H. Host Immunity Following Near-Infrared Photoimmunotherapy is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. Cancer Immunol. Res. 2019, 7, 401–413.
    22. Roskoski, R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79, 34–74.
    23. Xu, M.J.; Johnson, D.E.; Grandis, J.R. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017, 36, 463–473.
    24. Nicholson, R.; Gee, J.; Harper, M. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37, 9–15.
    25. Nagaya, T.; Sato, K.; Harada, T.; Nakamura, Y.; Choyke, P.L.; Kobayashi, H. Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS ONE 2015, 10, e0136829.
    26. Nakamura, Y.; Ohler, Z.W.; Householder, D.; Nagaya, T.; Sato, K.; Okuyama, S.; Ogata, F.; Daar, D.; Hoa, T.; Choyke, P.L.; et al. Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer. Mol. Cancer Ther. 2016, 16, 408–414.
    27. Nagaya, T.; Okuyama, S.; Ogata, F.; Maruoka, Y.; Knapp, D.W.; Karagiannis, S.N.; Fazekas-Singer, J.; Choyke, P.L.; Leblanc, A.K.; Jensen-Jarolim, E.; et al. Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. Oncotarget 2018, 9, 19026–19038.
    28. Siddiqui, M.R.; Railkar, R.; Sanford, T.; Crooks, D.R.; Eckhaus, M.A.; Haines, D.; Choyke, P.L.; Kobayashi, H.; Agarwal, P.K. Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Sci. Rep. 2019, 9, 2084.
    29. Burley, T.A.; Mączyńska, J.; Shah, A.; Szopa, W.; Harrington, K.J.; Boult, J.K.; Mrozek-Wilczkiewicz, A.; Vinci, M.; Bamber, J.C.; Kaspera, W.; et al. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. Int. J. Cancer 2018, 142, 2363–2374.
    30. Kalyankrishna, S.; Grandis, J.R. Epidermal Growth Factor Receptor Biology in Head and Neck Cancer. J. Clin. Oncol. 2006, 24, 2666–2672.
    31. ClinicalTrials.gov. Study of RM-1929 and Photoimmunotherapy in Patients with Recurrent Head and Neck Cancer. Available online: (accessed on 26 February 2021).
    32. Libermann, T.A.; Razon, N.; Bartal, A.D.; Yarden, Y.; Schlessinger, J.; Soreq, H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984, 44, 753–760.
    33. Libermann, T.A.; Nusbaum, H.R.; Razon, N.; Kris, R.; Lax, I.; Soreq, H.; Whittle, N.; Waterfield, M.D.; Ullrich, A.; Schlessinger, J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nat. Cell Biol. 1985, 313, 144–147.
    34. Shinojima, N.; Tada, K.; Shiraishi, S.; Kamiryo, T.; Kochi, M.; Nakamura, H.; Makino, K.; Saya, H.; Hirano, H.; Kuratsu, J.-I.; et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63, 6962–6970.
    35. Mukaida, H.; Toi, M.; Hirai, T.; Yamashita, Y.; Toge, T. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991, 68, 142–148.
    36. Itakura, Y.; Sasano, H.; Shiga, C.; Furukawa, Y.; Shiga, K.; Mori, S.; Nagura, H. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994, 74, 795–804.
    37. Wang, K.L.; Wu, T.-T.; Choi, I.S.; Wang, H.; Resetkova, E.; Correa, A.M.; Hofstetter, W.L.; Swisher, S.G.; Ajani, J.A.; Rashid, A.; et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas. Cancer 2007, 109, 658–667.
    38. Navarini, D.; Gurski, R.R.; Madalosso, C.A.; Aita, L.; Meurer, L.; Fornari, F. Epidermal Growth Factor Receptor Expression in Esophageal Adenocarcinoma: Relationship with Tumor Stage and Survival after Esophagectomy. Gastroenterol. Res. Pract. 2012, 2012, 1–5.
    39. Yacoub, L.; Goldman, H.; Odze, R.D. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett’s-associated neoplasia: Correlation with prognosis. Mod. Pathol. 1997, 10, 105–112.
    40. Herbst, R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. 2004, 59, 21–26.
    41. Burness, M.L.; Grushko, T.A.; Olopade, O.I. Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer: Promising Clinical Target or Only a Marker? Cancer J. 2010, 16, 23–32.
    42. Changavi, A.A.; Shashikala, A.; Ramji, A.S. Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas. J. Lab. Phys. 2015, 7, 079–083.
    43. Cheng, G.; Mei, Y.; Pan, X.; Liu, M.; Wu, S. Expression of HER2/c-erbB-2, EGFR protein in gastric carcinoma and its clinical significance. Open Life Sci. 2019, 14, 119–125.
    44. Gao, M.; Liang, X.-J.; Zhang, Z.-S.; Ma, W.; Chang, Z.-W.; Zhang, M.-Z. Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features. Asian Pac. J. Trop. Med. 2013, 6, 260–264.
    45. Galizia, G.; Lieto, E.; Orditura, M.; Castellano, P.; La Mura, A.; Imperatore, V.; Pinto, M.; Zamboli, A.; De Vita, F.; Ferraraccio, F. Epidermal Growth Factor Receptor (EGFR) Expression is Associated with a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery. World J. Surg. 2007, 31, 1458–1468.
    46. Huang, C.-W.; Chen, Y.-T.; Tsai, H.-L.; Yeh, Y.-S.; Su, W.-C.; Ma, C.-J.; Tsai, T.-N.; Wang, J.-Y. EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. Oncotarget 2017, 8, 114663–114676.
    47. Liu, J.; Zhou, Q.; Xu, J.; Wang, J.; Zhang, Y. Detection of EGFR expression in patients with colorectal cancer and the therapeutic effect of cetuximab. J. B.U.ON. Off. J. Balk. Union Oncol. 2016, 21, 95–100.
    48. Theodoropoulos, G.E.; Karafoka, E.; Papailiou, J.G.; Stamopoulos, P.; Zambirinis, C.P.; Bramis, K.; Panoussopoulos, S.-G.; Leandros, E.; Bramis, J. P53 and EGFR expression in colorectal cancer: A reappraisal of ‘old’ tissue markers in patients with long follow-up. Anticancer. Res. 2009, 29, 785–791.
    49. Spano, J.-P.; Lagorce, C.; Atlan, D.; Milano, G.; Domont, J.; Benamouzig, R.; Attar, A.; Benichou, J.; Martin, A.; Morere, J.-F.; et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005, 16, 102–108.
    50. Park, S.J.; Gu, M.J.; Lee, D.S.; Yun, S.S.; Kim, H.J.; Choi, J.H. EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma. Int. J. Clin. Exp. Pathol. 2015, 8, 8298–8304.
    51. Handra-Luca, A.; Hammel, P.; Sauvanet, A.; Lesty, C.; Ruszniewski, P.; Couvelard, A. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. J. Clin. Pathol. 2014, 67, 295–300.
    52. Bloomston, M.; Bhardwaj, A.; Ellison, E.C.; Frankel, W.L. Epidermal Growth Factor Receptor Expression in Pancreatic Carcinoma Using Tissue Microarray Technique. Dig. Surg. 2006, 23, 74–79.
    53. Chow, N.H.; Chan, S.H.; Tzai, T.S.; Ho, C.L.; Liu, H.S. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 2001, 7, 1957–1962.
    54. Sheng, Q.; Liu, J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 2011, 104, 1241–1245.
    55. Soonthornthum, T.; Arias-Pulido, H.; Joste, N.; Lomo, L.; Muller, C.; Rutledge, T.; Verschraegen, C. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann. Oncol. 2011, 22, 2166–2178.
    56. King, C.R.; Kraus, M.H.; Aaronson, S.A. Amplification of a novel verbB-related gene in a human mammary carcinoma. Science 1985, 229, 974–976.
    57. Arkhipov, A.; Shan, Y.; Kim, E.T.; Dror, R.O.; Shaw, D.E. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. eLife 2013, 2, e00708.
    58. Meric-Bernstam, F.; Johnson, A.M.; Dumbrava, E.E.I.; Raghav, K.; Balaji, K.; Bhatt, M.; Murthy, R.K.; Rodon, J.; Piha-Paul, S.A. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin. Cancer Res. 2019, 25, 2033–2041.
    59. Krishnamurti, U.; Silverman, J.F. HER2 in Breast Cancer. Adv. Anat. Pathol. 2014, 21, 100–107.
    60. Oh, D.-Y.; Bang, Y.-J. HER2-targeted therapies—A role beyond breast cancer. Nat. Rev. Clin. Oncol. 2020, 17, 33–48.
    61. Gravalos, C.; Jimeno, A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008, 19, 1523–1529.
    62. Zhan, N.; Dong, W.-G.; Tang, Y.-F.; Wang, Z.-S.; Xiong, C.-L. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med. Oncol. 2012, 29, 933–940.
    63. Van Cutsem, E.; Bang, Y.-J.; Feng-Yi, F.; Xu, J.M.; Lee, K.-W.; Jiao, S.-C.; Chong, J.L.; López-Sanchez, R.I.; Price, T.; Gladkov, O.; et al. HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015, 18, 476–484.
    64. Hartmans, E.; Linssen, M.D.; Sikkens, C.; Levens, A.; Witjes, M.J.; Van Dam, G.M.; Nagengast, W.B. Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines. Oncotarget 2017, 8, 29846–29856.
    65. Sato, K.; Nagaya, T.; Choyke, P.L.; Kobayashi, H. Near Infrared Photoimmunotherapy in the Treatment of Pleural Disseminated NSCLC: Preclinical Experience. Theranostics 2015, 5, 698–709.
    66. Sato, K.; Hanaoka, H.; Watanabe, R.; Nakajima, T.; Choyke, P.L.; Kobayashi, H. Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer. Mol. Cancer Ther. 2015, 14, 141–150.
    67. Ito, K.; Mitsunaga, M.; Arihiro, S.; Saruta, M.; Matsuoka, M.; Kobayashi, H.; Tajiri, H. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC Cancer 2016, 16, 37.
    68. Ito, K.; Mitsunaga, M.; Nishimura, T.; Kobayashi, H.; Tajiri, H. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: An assessment of phototherapeutic effect based on fluorescence molecular imaging. Oncotarget 2016, 7, 14143–14152.
    69. Chen, C.; Zhao, S.; Karnad, A.; Freeman, J.W. The biology and role of CD44 in cancer progression: Therapeutic implications. J. Hematol. Oncol. 2018, 11, 64.
    70. Yan, Y.; Zuo, X.; Wei, D. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl. Med. 2015, 4, 1033–1043.
    71. Chen, J.; Zhou, J.; Lu, J.; Xiong, H.; Shi, X.; Gong, L. Significance of CD44 expression in head and neck cancer: A systemic review and meta-analysis. BMC Cancer 2014, 14, 15.
    72. Nagaya, T.; Nakamura, Y.; Okuyama, S.; Ogata, F.; Maruoka, Y.; Choyke, P.L.; Allen, C.; Kobayashi, H. Syngeneic Mouse Models of Oral Cancer are Effectively Targeted by Anti-CD44-Based NIR-PIT. Mol. Cancer Res. 2017, 15, 1667–1677.
    73. Wakiyama, H.; Furusawa, A.; Okada, R.; Inagaki, F.; Kato, T.; Maruoka, Y.; Choyke, P.L.; Kobayashi, H. Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. Cancers 2020, 12, 3747.
    74. Maruoka, Y.; Furusawa, A.; Okada, R.; Inagaki, F.; Fujimura, D.; Wakiyama, H.; Kato, T.; Nagaya, T.; Choyke, P.L.; Kobayashi, H. Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models. Vaccines 2020, 8, 528.
    75. Kemper, K.; Sprick, M.R.; De Bree, M.; Scopelliti, A.; Vermeulen, L.; Hoek, M.; Zeilstra, J.; Pals, S.T.; Mehmet, H.; Stassi, G.; et al. The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation. Cancer Res. 2010, 70, 719–729.
    76. Jing, H.; Weidensteiner, C.; Reichardt, W.; Gaedicke, S.; Zhu, X.; Grosu, A.-L.; Kobayashi, H.; Niedermann, G. Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics 2016, 6, 862–874.
    77. Nagaya, T.; Nakamura, Y.; Okuyama, S.; Ogata, F.; Maruoka, Y.; Choyke, P.L.; Kobayashi, H. Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. Mol. Cancer Res. 2017, 15, 1153–1162.
    78. Haberkorn, U.; Eder, M.; Kopka, K.; Babich, J.W.; Eisenhut, M. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 2016, 22, 9–15.
    79. Hammarström, S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 1999, 9, 67–81.
    80. Grunnet, M.; Sorensen, J. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012, 76, 138–143.
    81. Campos-Da-Paz, M.; Dórea, J.G.; Galdino, A.S.; Lacava, Z.G.M.; Santos, M.D.F.M.A. Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches. Recent Pat. Biotechnol. 2018, 12, 269–279.
    82. Tiernan, J.P.; Perry, S.L.; Verghese, E.T.; West, N.P.; Yeluri, S.; Jayne, D.G.; Hughes, T.A. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br. J. Cancer 2013, 108, 662–667.
    83. Maawy, A.A.; Hiroshima, Y.; Zhang, Y.; Heim, R.; Makings, L.; Garcia-Guzman, M.; Luiken, G.A.; Kobayashi, H.; Hoffman, R.M.; Bouvet, M. Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer. PLoS ONE 2015, 10, e0121989.
    84. Shirasu, N.; Yamada, H.; Shibaguchi, H.; Kuroki, M.; Kuroki, M. Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int. J. Cancer 2014, 135, 2697–2710.
    85. Hiroshima, Y.; Maawy, A.; Zhang, Y.; Guzman, M.G.; Heim, R.; Makings, L.; Luiken, G.A.; Kobayashi, H.; Tanaka, K.; Endo, I.; et al. Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Ann. Surg. Oncol. 2015, 22, 1469–1474.
    86. Maawy, A.A.; Hiroshima, Y.; Zhang, Y.; Garcia-Guzman, M.; Luiken, G.A.; Kobayashi, H.; Hoffman, R.M.; Bouvet, M. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models. J. Surg. Res. 2015, 197, 5–11.
    87. Nishinaga, Y.; Sato, K.; Yasui, H.; Taki, S.; Takahashi, K.; Shimizu, M.; Endo, R.; Koike, C.; Kuramoto, N.; Nakamura, S.; et al. Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin. Cells 2020, 9, 1019.
    88. Bibby, A.C.; Tsim, S.; Kanellakis, N.; Ball, H.; Talbot, D.C.; Blyth, K.G.; Maskell, N.A.; Psallidas, I. Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment. Eur. Respir. Rev. 2016, 25, 472–486.
    89. Schacht, V.; Ramirez, M.I.; Hong, Y.; Hirakawa, S.; Feng, D.; Harvey, N.; Williams, M.; Dvorak, A.M.; Dvorak, H.F.; Oliver, G.; et al. T1 /podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003, 22, 3546–3556.
    90. Quintanilla, M.; Montero-Montero, L.; Renart, J.; Martín-Villar, E. Podoplanin in Inflammation and Cancer. Int. J. Mol. Sci. 2019, 20, 707.
    91. Chuang, W.-Y.; Chang, Y.-S.; Yeh, C.-J.; Wu, Y.-C.; Hsueh, C. Role of podoplanin expression in squamous cell carcinoma of upper aerodigestive tract. Histol. Histopathol. 2013, 28, 293–299.
    92. Wicki, A.; Christofori, G. The potential role of podoplanin in tumour invasion. Br. J. Cancer 2006, 96, 1–5.
    93. Wicki, A.; Lehembre, F.; Wick, N.; Hantusch, B.; Kerjaschki, D.; Christofori, G. Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006, 9, 261–272.
    94. Ordóñez, N.G. Application of Mesothelin Immunostaining in Tumor Diagnosis. Am. J. Surg. Pathol. 2003, 27, 1418–1428.
    95. Hassan, R.; Ho, M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 2008, 44, 46–53.
    96. Nagaya, T.; Nakamura, Y.; Sato, K.; Zhang, Y.-F.; Ni, M.; Choyke, P.L.; Ho, M.; Kobayashi, H. Near infrared photoimmunotherapy with an anti-mesothelin antibody. Oncotarget 2016, 7, 23361–23369.
    97. Sakamoto, J.; Kojima, H.; Kato, J.; Hamashima, H.; Suzuki, H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother. Pharmacol. 2000, 46, S27–S32.
    98. Heath, J.K.; White, S.J.; Johnstone, C.N.; Catimel, B.; Simpson, R.J.; Moritz, R.L.; Tu, G.-F.; Ji, H.; Whitehead, R.H.; Groenen, L.C.; et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. USA 1997, 94, 469–474.
    99. Wei, D.; Tao, Z.; Shi, Q.; Wang, L.; Liu, L.; She, T.; Yi, Q.; Wen, X.; Liu, L.; Li, S.; et al. Selective Photokilling of Colorectal Tumors by Near-Infrared Photoimmunotherapy with a GPA33-Targeted Single-Chain Antibody Variable Fragment Conjugate. Mol. Pharm. 2020, 17, 2508–2517.
    100. Goldenberg, D.M.; Cardillo, T.M.; Govindan, S.V.; Rossi, E.A.; Sharkey, R.M. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 2015, 6, 22496–22512.
    101. Shvartsur, A.; Bonavida, B. Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes Cancer 2014, 6, 84–105.
    102. Nishimura, T.; Mitsunaga, M.; Sawada, R.; Saruta, M.; Kobayashi, H.; Matsumoto, N.; Kanke, T.; Yanai, H.; Nakamura, K. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. Cancer Med. 2019, 8, 7781–7792.
    103. Bartolomé, R.A.; Barderas, R.; Torres, S.; Fernandez-Aceñero, M.J.; Mendes, M.; García-Foncillas, J.; Lopez-Lucendo, M.; Casal, J.I. Cadherin-17 interacts with α2β1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene 2013, 33, 1658–1669.
    104. Panarelli, N.C.; Yantiss, R.K.; Yeh, M.M.; Liu, Y.; Chen, Y.-T. Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas with Higher Sensitivity Than CDX2. Am. J. Clin. Pathol. 2012, 138, 211–222.
    105. Lum, Y.-L.; Luk, J.M.; Staunton, D.E.; Ng, D.K.P.; Fong, W.-P. Cadherin-17 Targeted Near-Infrared Photoimmunotherapy for Treatment of Gastrointestinal Cancer. Mol. Pharm. 2020, 17, 3941–3951.
    106. Owen, D.H.; Giffin, M.J.; Bailis, J.M.; Smit, M.-A.D.; Carbone, D.P.; He, K. DLL3: An emerging target in small cell lung cancer. J. Hematol. Oncol. 2019, 12, 61.
    107. Saunders, L.R.; Bankovich, A.J.; Anderson, W.C.; Aujay, M.A.; Bheddah, S.; Black, K.; Desai, R.; Escarpe, P.A.; Hampl, J.; Laysang, A.; et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 2015, 7, 302ra136.
    108. Isobe, Y.; Sato, K.; Nishinaga, Y.; Takahashi, K.; Taki, S.; Yasui, H.; Shimizu, M.; Endo, R.; Koike, C.; Kuramoto, N.; et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine 2020, 52, 102632.
    109. Rudin, C.M.; Pietanza, M.C.; Bauer, T.M.; Ready, N.; Morgensztern, D.; Glisson, B.S.; Byers, L.A.; Johnson, M.L.; Burris, H.A.; Robert, F.; et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017, 18, 42–51.
    110. Baumhoer, D.; Tornillo, L.; Stadlmann, S.; Roncalli, M.; Diamantis, E.K.; Terracciano, L.M. Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues. Am. J. Clin. Pathol. 2008, 129, 899–906.
    111. Silsirivanit, A. Glycosylation markers in cancer. Adv. Clin. Chem. 2019, 89, 189–213.
    112. Hanaoka, H.; Nagaya, T.; Sato, K.; Nakamura, Y.; Watanabe, R.; Harada, T.; Gao, W.; Feng, M.; Phung, Y.; Kim, I.; et al. Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy. Mol. Pharm. 2015, 12, 2151–2157.
    113. Hanaoka, H.; Nakajima, T.; Sato, K.; Watanabe, R.; Phung, Y.; Gao, W.; Harada, T.; Kim, I.; Paik, C.H.; Choyke, P.L.; et al. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine 2015, 10, 1139–1147.
    114. Hwang, J.H.; Kimmey, M.B. The incidental upper gastrointestinal subepithelial mass. Gastroenterology 2004, 126, 301–307.
    115. Fujimoto, S.; Muguruma, N.; Okamoto, K.; Kurihara, T.; Sato, Y.; Miyamoto, Y.; Kitamura, S.; Miyamoto, H.; Taguchi, T.; Tsuneyama, K.; et al. A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors. Theranostics 2018, 8, 2313–2328.
    116. Nishida, T.; Blay, J.-Y.; Hirota, S.; Kitagawa, Y.; Kang, Y.-K. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 2016, 19, 3–14.
    117. Sabattini, E.; Bacci, F.; Sagramoso, C.; Pileri, S.A. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica 2010, 102, 83–87.
    118. Chung, C. Current targeted therapies in lymphomas. Am. J. Health Pharm. 2019, 76, 1825–1834.
    119. Nagaya, T.; Nakamura, Y.; Sato, K.; Harada, T.; Choyke, P.L.; Kobayashi, H. Near infrared photoimmunotherapy of B-cell lymphoma. Mol. Oncol. 2016, 10, 1404–1414.
    120. Heryanto, Y.-D.; Hanaoka, H.; Nakajima, T.; Yamaguchi, A.; Tsushima, Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: Comparative evaluation with radioimmunotherapy in tumor xenografts. Ann. Nucl. Med. 2017, 31, 669–677.
    121. Alhothali, G.I. Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach. Int. J. Health Sci. 2013, 7, 220–239.
    122. Magro, C.M.; Dyrsen, M.E. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J. Cutan. Pathol. 2008, 35, 1040–1049.
    123. Silic-Benussi, M.; Saponeri, A.; Michelotto, A.; Russo, I.; Colombo, A.; Pelizzo, M.G.; Ciminale, V.; Alaibac, M. Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides. Expert Opin. Biol. Ther. 2020, 1–5.
    124. Berkowitz, J.L.; Janik, J.E.; Stewart, D.M.; Jaffe, E.S.; Stetler-Stevenson, M.; Shih, J.H.; Fleisher, T.A.; Turner, M.; Urquhart, N.E.; Wharfe, G.H.; et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin. Immunol. 2014, 155, 176–187.
    125. Dye, D.E.; Emedic, S.; Eziman, M.; Coombe, D.R. Melanoma Biomolecules: Independently Identified but Functionally Intertwined. Front. Oncol. 2013, 3, 252.
    126. Wei, W.; Jiang, D.; Ehlerding, E.B.; Barnhart, T.E.; Yang, Y.; Engle, J.W.; Luo, Q.-Y.; Huang, P.; Cai, W. CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. Adv. Sci. 2019, 6, 1801237.
    127. Hama, Y.; Urano, Y.; Koyama, Y.; Kamiya, M.; Bernardo, M.; Paik, R.S.; Krishna, M.C.; Choyke, P.L.; Kobayashi, H. In Vivo Spectral Fluorescence Imaging of Submillimeter Peritoneal Cancer Implants Using a Lectin-Targeted Optical Agent. Neoplasia 2006, 8, 607–612.
    128. Harada, T.; Nakamura, Y.; Sato, K.; Nagaya, T.; Okuyama, S.; Ogata, F.; Choyke, P.L.; Kobayashi, H. Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer. Oncotarget 2016, 7, 79408–79416.
    129. Patel, S.P.; Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol. Cancer Ther. 2015, 14, 847–856.
    130. Barber, D.L.; Wherry, E.J.; Masopust, D.; Zhu, B.; Allison, J.P.; Sharpe, A.H.; Freeman, G.J.; Ahmed, R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nat. Cell Biol. 2005, 439, 682–687.
    131. Sharpe, A.H.; Wherry, E.J.; Ahmed, R.; Freeman, G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 2007, 8, 239–245.
    132. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 2020, 11, 3801.
    133. Nagaya, T.; Nakamura, Y.; Sato, K.; Harada, T.; Choyke, P.L.; Hodge, J.W.; Schlom, J.; Kobayashi, H. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget 2017, 8, 8807–8817.
    More